Metagenomi Therapeutics, Inc. MGX
As ofNov 19, 2026, 3:38 PM EST
- YTD
- -62.28%
- 1 year
- -62.04%
5D -0.0960 (-13.45%)
- Market cap
- 23.10M
- Revenue (ttm)
- 55.08M
- Profit margin
- -134.27%
- EPS (ttm)
- -2.50
- Shares out
- 37.42M
- Forward P/E
- -1.38
- YTD return
- -62.28%
- 1-year return
- -62.04%
- Volume
- 111.80K
- Avg volume
- 163.39K
- Open
- 0.63
- Previous close
- 0.6318
- Day's range
- 0.61 – 0.6423
- 52-week range
- 0.60 – 1.87
- Analysts
- Strong Buy
- Price target
- 18.40 (+2911.0%)
Key statistics
- 50-day average
- 2.31
- 200-day average
- 4.77
- Enterprise value
- -76.95M
- Price / sales
- 2.72
- Price / book
- 0.59
- Revenue growth
- -6.90%
- Free cash flow
- -73.89M
- Total cash
- 274.59M
- Total debt
- 46.07M
- Return on equity
- -30.34%
- Short % of float
- 1.00%
Fundamental scorecard
4 of 25 checks passed on MGX’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.70 | -0.45 | +0.25 | +35.71% |
| Aug 14, 2024 | Jun 1, 2024 | -0.59 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.59 | -0.29 | +0.30 | +50.85% |
| May 14, 2024 | Mar 1, 2024 | -0.95 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.95 | -1.19 | -0.24 | -25.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 5, 2024 | Chardan Capital | main | Buy | Buy |
About Metagenomi Therapeutics, Inc.
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metagenomi.co
News
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Transcript Metagenomi Therapeutics Receives FDA Clearance For Its Investigational New Drug Application For MGX-001 To Treat Hemophilia A
Metagenomi Therapeutics To Present Presentation On Preclinical Data Of MGX-001 At 68th American Society Of Hematology Annual Meeting
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on MGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAYER HEALTHCARE L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 12, 2024 | 0 |
| BORGES LUIS | Officer | Stock Award(Grant) | Mar 31, 2024 | 69,316 |
| DELANEY SIMREN | Officer | Stock Award(Grant) | Mar 31, 2024 | 93,892 |
| HARNEST SIMON | Officer | Stock Award(Grant) | Mar 31, 2024 | 122,664 |
| IRISH JIAN PH.D. | President | Stock Award(Grant) | Mar 31, 2024 | 655,898 |
| NOONBERG SARAH B | Officer | Stock Award(Grant) | Mar 31, 2024 | 100,374 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Novo Holdings A/S | 4.81% | 1,800,000 | 7.22M | Sep 29, 2024 |
| RA Capital Management, L.P. | 3.49% | 1,305,239 | 5.23M | Sep 29, 2024 |
| Farallon Capital Management LLC | 2.82% | 1,057,201 | 4.24M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 2.76% | 1,034,002 | 4.15M | Sep 29, 2024 |
| Citadel Advisors Llc | 2.15% | 804,462 | 3.23M | Sep 29, 2024 |
| HHLR Advisors, LTD | 2.08% | 777,768 | 3.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.47% | 177,208 | 710.60K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.44% | 163,172 | 654.32K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.38% | 141,338 | 566.76K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 142,625 | 571.93K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.25% | 92,200 | 369.72K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.17% | 63,604 | 255.05K | Aug 30, 2024 |
